vTv Therapeutics (VTVT) announced that it has expanded its license agreement with Newsoara Biopharma to provide Newsoara with global rights to the Company’s PDE4 inhibitor, HPP737. Pursuant to the amended license agreement, Newsoara has obtained an exclusive, worldwide license to develop and commercialize Company’s PDE4 inhibitor, HPP737, in exchange for an upfront payment and potential future milestone payments and royalties on net sales. In addition to the upfront payment of $20 million, the amended license with Newsoara includes future development milestones of up to approximately $50 million, future sales milestones of up to $65 million, and tiered royalties based on sales.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- vTv Therapeutics price target raised to $49 from $40 at BTIG
- vTv Therapeutics initiated with a Buy at Roth Capital
- vTv Therapeutics: Late-Stage Cadisegliatin Data, Differentiated Mechanism, and Partnered T2D Expansion Underpin Buy Rating and $40 Target
- vTv Therapeutics initiated with a Buy at TD Cowen
- Paradigm-Shifting Potential in Type 1 Diabetes: vTv Therapeutics’ Cadisegliatin Supports Buy Rating and Significant Upside